trending Market Intelligence /marketintelligence/en/news-insights/trending/Q0aN9VW4jBAo6BM3IT6XTw2 content esgSubNav
In This List

Eleven Biotherapeutics CFO resigns; interim replacement named

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Eleven Biotherapeutics CFO resigns; interim replacement named

John McCabe resigned as CFO of Eleven Biotherapeutics Inc., effective Oct. 20.

McCabe did not resign due to any disagreements relating to the company's operations, policies or practices or any other company officer or director.

Eleven Biotherapeutics appointed Richard Fitzgerald as interim CFO, effective Oct. 13.

Fitzgerald most recently served as a consultant to private life science based companies from July through October. Previously, Fitzgerald served as CFO of medical device maker PAVmed Inc. from October 2015 through March 2017.